Earnings Calls In Brief
This article was originally published in The Gray Sheet
Johnson & Johnson’s mid-year Synthes purchase drives third-quarter revenue growth. Abbott spin-off on track. More news briefs.
You may also be interested in...
Recent new product launches and approvals include Boston Scientific’s novel S-ICD subcutaneous implantable cardioverter defibrillator, Globus Medical’s Secure-C artificial cervical disc and ConforMIS’ next-generation iTotal G2 total knee replacement.
Potential growth drivers identified by the firm during its April 19 first-quarter earnings call include the Ingenio family of pacemakers and BSX-manufactured Promus Element everolimus-eluting stent system.
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.